Xtant Medical Holdings (XMS) Stock Price & Analysis
XMS Stock Chart & Stats
- Day’s Range
- EUR 0.25 - EUR 0.25
- 52-Week Range
- EUR 0.24 - EUR 0.78
- Previous Close
- EUR 0.25
- Volume
- 0
- Average Volume (3M)
- 57
- Market Cap
- EUR 35.08M
- Enterprise Value
- EUR 74.84M
- Total Cash (Recent Filing)
- EUR 9.87M
- Total Debt (Recent Filing)
- EUR 26.01M
- Price to Earnings (P/E)
- ―
- Beta
- 0.54
- Next Earnings
- Nov 06, 2026 (Est.)
- EPS Estimate
- -0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Solid Gross Margins
Despite volatile revenue and earnings, gross margin remained roughly in the low-60% range across 2025 and TTM. This indicates the product portfolio retains favorable underlying economics, providing a foundation for future operating leverage if biologics growth and procedural volumes recover.
Improved Balance Sheet
Lower leverage and a positive, sizable equity base provide greater resilience than in prior periods. This balance-sheet improvement supports continued investment in commercial initiatives and gives Xtant more capacity to manage operating volatility, although sustained losses could reverse that progress.
Expanded Commercial Platform
The Dilon distribution agreement and materially larger sales organization expand hospital and surgeon coverage while creating cross-selling opportunities for Xtant’s biologics. This broader commercial reach can support durable adoption of HEMOBLAST and existing products as integration progresses.
Bears Say
Revenue Contraction
The sharp quarterly decline and lower annual guidance show that recent commercial momentum has not yet offset asset sales, license-revenue cessation, and biologics weakness. Prolonged top-line pressure would reduce operating leverage and make recovery in earnings and cash generation less certain.
Profitability Deterioration
Margin compression combined with a swing to negative adjusted EBITDA indicates that weaker volume, product mix, and operating costs are currently overwhelming the company’s gross-profit base. If these pressures persist, investment in growth initiatives could produce less financial benefit and prolong losses.
Weak Cash Generation
The reversal from strong 2025 cash generation to modest operating cash flow and slightly negative free cash flow reduces internal funding capacity. Continued cash-flow volatility could constrain product development, sales expansion, and debt-management flexibility over the next several quarters.
Xtant Medical Holdings News
XMS FAQ
What was Xtant Medical Holdings’s price range in the past 12 months?
What is Xtant Medical Holdings’s market cap?
When is Xtant Medical Holdings’s upcoming earnings report date?
How were Xtant Medical Holdings’s earnings last quarter?
Is Xtant Medical Holdings overvalued?
Does Xtant Medical Holdings pay dividends?
What is Xtant Medical Holdings’s EPS estimate?
How many shares outstanding does Xtant Medical Holdings have?
What happened to Xtant Medical Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Xtant Medical Holdings?
What is the TipRanks Smart Score and how is it calculated?
Xtant Medical Holdings Stock Smart Score
Company Description
Xtant Medical Holdings
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Sean E. Browne
- Employees
- 151
- Website
- www.xtantmedical.com
- Address
- 664 Cruiser Lane, Belgrade, MT, 59714, US
Xtant Medical Holdings (XMS) Earnings & Revenues
XMS Earnings Call
Earnings Call SentimentNegative
The call presents meaningful strategic and commercial progress — notably the Dilon distribution agreement, integration of 17 new sales reps, product launches (Trivium Shaped) and expanded TAM — which position Xtant for future growth. However, the quarter showed significant near-term financial deterioration: sharp year-over-year revenue decline, gross margin compression, a swing to a net loss and negative adjusted EBITDA, reduced cash balances and a modestly reduced full-year revenue guide. Many negative results are tied to one-time transitions (asset sales, license cessation, Dilon integration) and strategic investments, but the immediate financial metrics are weak while visibility into near-term cash/earnings recovery remains uncertain.
View all DE:XMS earnings summariesXMS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 2 | 0 | 10 |